Pluristem gains FDA approval for new manufacturing plant in Israel

03/10/2014 | Globes (Israel)

The FDA has granted Pluristem Therapeutics approval to use its new manufacturing plant in Haifa, Israel, allowing it to take part in advanced clinical studies in the U.S. The facility features the company's fully automated 3D cell expansion platform for manufacturing stem cells.

View Full Article in:

Globes (Israel)

Published in Brief:

SmartBrief Job Listings for Health Care